Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants

The Hematology Journal : the Official Journal of the European Haematology Association
A GratwohlChronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation EBMT

Abstract

The male H-Y antigen is recognised as a minor histocompatibility antigen with debatable relevance and has not been substantiated thus far in clinical solid organ transplantation. An increase in transplant-related mortality in male recipients of female stem cells has been recognised and attributed to graft vs host effect against H-Y; in contrast, decreased incidence of relapse, a graft vs leukaemia effect has not yet been described. To detect potentially small but significant differences, we performed an analysis in a highly homogeneous group. We have analysed 782 patients, 438 males and 344 females, who were transplanted from HLA-identical female donors for CML in 1st chronic phase between 1989 and 1997. The risk of transplant related mortality (TRM) and relapse incidence (RI) were compared for male and female recipients over three successive time periods, zero to three months, three months to two years and two to five years post-transplant. Both groups were comparable for known risk factors prior to transplant. The cumulative risk of TRM at five years was significantly higher in males (42%, s.e.=3.6) than in females (27%, s.e.=2.8; P=0.02) with no overall effect on risk of relapse. Within the three specified time intervals pos...Continue Reading

Citations

Jun 23, 2009·Journal of the American Society of Nephrology : JASN·S Joseph Kim, John S Gill
Oct 8, 2009·Circulation. Heart Failure·Jennifer C Matthews, Keith D Aaronson
Oct 24, 2002·Current Opinion in Hematology·J H F FalkenburgR Willemze
Feb 4, 2003·Nature Reviews. Immunology·Peter Parham, Karina L McQueen
Sep 19, 2003·Wiener klinische Wochenschrift·Christian SillaberPeter Valent
Oct 3, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·M SternA Gratwohl
Nov 11, 2009·Epidemiology·Henriette Svarre NielsenAnne-Marie N Andersen
Jun 17, 2014·Chimerism·Astrid Gs van HalterenMirjam Fechter
Aug 6, 2014·American Journal of Reproductive Immunology : AJRI·Elizabeth Ann L EnningaShernan G Holtan
Nov 3, 2016·Bone Marrow Transplantation·M RembergerP Ljungman
May 12, 2005·Cancer Immunology, Immunotherapy : CII·Johannes ScheteligMartin Bornhäuser
May 3, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Robert J BiggarRobin Broadhead
Apr 13, 2011·Human Reproduction Update·Henriette Svarre Nielsen
Jul 8, 2011·American Journal of Reproductive Immunology : AJRI·Ole Bjarne ChristiansenHenriette Svarre Nielsen
Feb 13, 2013·American Journal of Reproductive Immunology : AJRI·Caitlin Linscheid, Margaret G Petroff
Feb 13, 2019·Transplantation·Anette MelkMarina Berenguer
Feb 2, 2011·Epidemiology·Laust H MortensenAnne-Marie Nybo Andersen
Jun 12, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·David LissauerPaul A H Moss
Nov 17, 2009·Expert Reviews in Molecular Medicine·David M LissauerMark D Kilby
Jan 31, 2008·Dermatology : International Journal for Clinical and Investigative Dermatology·Peter HäusermannAlois Gratwohl
Nov 25, 2016·Frontiers in Immunology·Mateja Kralj JuricHildegard T Greinix

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.